trial · primary record
Tezepelumab
Eosinophilic Esophagitis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 368 |
| Primary completion | 2027-03-23 |
| Primary endpoint | Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels |
| Registry ID | NCT05583227 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:44.610Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05583227
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.